Cipher Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Cipher Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Cipher Pharmaceuticals Inc Strategy Report
- Understand Cipher Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company’s major products comprise actikerall, to treat slightly palpable and moderately thick hyperkeratotic actinic keratosis (grade I/II) of the face, forehead, and balding scalp; epuris, to treat severe nodular and inflammatory acne, acne con globate and recalcitrant acne; ozanex for the topical treatment of impetigo, vaniqa, to treat unwanted facial hair in women. its pipeline products include treprostinil sodium, to treat pulmonary arterial hypertension; MOB-015, to treat onychomycosis; CF-101, to treat severe plaque psoriasis and rheumatoid arthritis, DTR-001, for tattoo removal. The company carries out various phases of clinical trials. Cipher is headquartered in Mississauga, Ontario, Canada.
Headquarters
Canada
Address
5750 Explorer Drive, Suite 404, Mississauga, Ontario, L4W0A9
Website
www.cipherpharma.com
Telephone
1 905 6025840
No of Employees
6
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CPH (TSE)
Revenue (2022)
$21.2M
2.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-23.5%
(2022 vs 2021)
Market Cap*
$150.1M
Net Profit Margin (2022)
XYZ
-25.2%
(2022 vs 2021)
* As of and is in US$
Cipher Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Actikerall (to treat Slightly Palpable and Moderately Thick Hyperkeratotic Actinic Keratosis (Grade I/II) of the Face, Forehead and Balding Scalp) | Services | Actikerall |
| Epuris (to treat Severe Nodular and Inflammatory Acne, Acne Con Globate and Recalcitrant Acne) | Clinical Trails | Vaniqa |
| Ozanex (for the Topical Treatment of Impetigo) | Epuris | |
| XYZ | ||
| XYZ | ||
| XYZ |
Competitor Comparison
| Key Parameters | Cipher Pharmaceuticals Inc | Polydex Pharmaceuticals Ltd | Avricore Health Inc | Intellipharmaceutics International Inc | Antibe Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | Canada | Canada | Canada | Canada |
| City | Mississauga | Scarborough | Vancouver | Etobicoke | Toronto |
| State/Province | Ontario | Ontario | British Columbia | Ontario | Ontario |
| No. of Employees | 6 | 20 | - | 33 | 11 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Craig Mull | Chairman; Chief Executive Officer - Interim | Executive Board | - | - |
| Bryan Jacobs | Chief Financial Officer | Senior Management | - | - |
| Emilio Presti | Director - Sales and Marketing | Senior Management | - | - |
| Diane Gajewczyk | Vice President - Scientific and Medical Affairs | Senior Management | - | - |
| Harold Wolkin | Director | Non Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer